Phase 1 onCARlytics solid tumour trial advances to combination arm treatment Phase 1 trial of CD19 oncolytic virotherapy drug candidate onCARlytics cleared its first cohort within the intratumoral monotherapy arm of the study.

CARGO Therapeutics Announces Pricing of Initial Public Offering CARGO Therapeutics Announce Pricing of IPO

Teneobio Announces US FDA Clearance of Investigational New Drug Application for TNB-486 and the Initiation of Phase I Clinical Studies in Patients with B-cell Malignancies NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced today that their investigational new drug application (IND) for TNB-486, a bispecific...

Triumvira to Present Corporate Update at the Bloom Burton & Co. Healthcare Investor Conference HAMILTON, ON and HACKENSACK, NJ --(Marketwired - April 25, 2016) - Triumvira Immunologics Inc. today announced that its President and Chief Executive Officer Tony Fiorino, MD, PhD, will present a...